ストックスクリーナーアプリを入手
8.05
7.76%
0.58
プレマーケット:
8.06
0.010
+0.12%
前日終値:
$7.47
開ける：
$7.61
24時間の取引高:
4.73M
Relative Volume:
1.77
時価総額：
$585.35M
収益：
$409.00K
当期純損益:
$-101.35M
株価収益率:
-4.9387
EPS:
-1.63
ネットキャッシュフロー:
$-71.49M
1週間 パフォーマンス:
-15.44%
1か月 パフォーマンス:
+17.01%
6か月 パフォーマンス:
+0.12%
1年 パフォーマンス:
+206.08%
1日の値動き範囲:
$7.519
$8.4201
1週間の範囲:
$6.945
$9.70
52週間の値動き範囲:
$2.4821
$14.84
Altimmune Inc Stock (ALT) Company Profile
ALT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ALT | 8.05 | 585.35M | 409.00K | -101.35M | -71.49M | -1.63 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-29 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-01-24 | 開始されました | Goldman | Neutral |
| 2023-03-22 | ダウングレード | Goldman | Buy → Neutral |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-11 | 開始されました | Guggenheim | Buy |
| 2020-12-14 | 開始されました | Jefferies | Buy |
| 2020-11-12 | 繰り返されました | B. Riley Securities | Buy |
| 2020-09-25 | 開始されました | B. Riley FBR | Buy |
| 2020-08-14 | 開始されました | Evercore ISI | Outperform |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-07-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-02-24 | 再開されました | ROTH Capital | Buy |
| 2019-07-19 | 開始されました | ROTH Capital | Buy |
| 2017-10-09 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Altimmune Inc (ALT) 最新ニュース
FY2024 EPS Estimates for Altimmune Reduced by HC Wainwright - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Consensus Target Price from Analysts - MarketBeat
(ALT) Trading Report - Stock Traders Daily
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times
Altimmune's Pemvidutide Shows 68.5% Liver Fat Reduction in Phase 1b Trial Results | ALT Stock News - StockTitan
What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat
AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com
B. Riley Weighs in on Altimmune's Q1 Earnings (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Given Buy Rating at HC Wainwright - MarketBeat
Altimmune Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge (NASDAQ:ALT) - Seeking Alpha
Altimmune Unusual Options Activity For November 13 - Benzinga
Altimmune’s Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health (ALT) - Seeking Alpha
Altimmune provided key pipeline updates with Q3 report, says B. Riley - TipRanks
Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call Transcript - Insider Monkey
UBS Initiates Coverage of Altimmune (ALT) with Buy Recommendation - Nasdaq
GSA Capital Partners LLP Sells 148,530 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Earnings call: Altimmune reports progress on pemvidutide trials, financials - Investing.com India
Earnings call: Altimmune reports progress on pemvidutide trials, financials By Investing.com - Investing.com Canada
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding R&D Investments - GuruFocus.com
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... - Yahoo Finance
Altimmune (ALT) Stock Soars 27%: Phase 2 Data On Obesity Drug Ignites Market Optimism - Barchart
Altimmune Reports Q3 2024 Financial Results and Advances Drug Pipeline - TipRanks
Altimmune Stock Rallies 30% on Updates - citybiz
Altimmune stock rallies 30% on business updates, UBS buy rating - MSN
Altimmune stock rallies 30% on business updates, UBS buy rating (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Traders Purchase Large Volume of Altimmune Call Options (NASDAQ:ALT) - MarketBeat
Altimmune Inc Reports Q3 2024 Results: GAAP EPS of -$0.32 Beats Estimates, Revenue at $5,000 - GuruFocus.com
Altimmune Appoints Gregory Weaver as CFO for Growth - TipRanks
UBS Group Initiates Coverage on Altimmune (NASDAQ:ALT) - MarketBeat
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance
Altimmune Appoints Greg Weaver as CFO - citybiz
Altimmune Appoints Chief Financial Officer - Contract Pharma
Altimmune says ‘something raised attention of FDA’ - TipRanks
Altimmune appoints Greg Weaver as CFO - TipRanks
Altimmune Names Greg Weaver Chief Financial Officer - MarketWatch
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - The Manila Times
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer - Marketscreener.com
How Altimmune Could Grab a Big Chunk of the GLP-1 Market - MarketBeat
Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail
Institutional investors control 59% of Altimmune, Inc. (NASDAQ:ALT) and were rewarded last week after stock increased 11% - Simply Wall St
Altimmune advances obesity treatment into Phase 3 trials By Investing.com - Investing.com South Africa
Altimmune, FDA agree on efficacy measures for phase 3 trial of pemvidutide - Seeking Alpha
Altimmune advances obesity treatment into Phase 3 trials - Investing.com India
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity - The Manila Times
Altimmune Advances Obesity Drug: FDA Greenlights Major Phase 3 Program Design | ALT Stock News - StockTitan
Altimmune Inc (ALT) 財務データ
収益
当期純利益
現金流量
EPS
0.69%
6.90%
大文字化:
|
ボリューム (24 時間):